FDA Chimes in as Oculus Reportedly Preps Stock Sale

The U.S. Food and Drug Administration confirmed late Friday that Oculus Innovative Sciences (OCLS Quote) cannot make medical or drug-like claims about a diluted bleach product it sells to clean wounds.

The controversy over how Oculus markets Microcyn, an antiseptic sold over the counter for $20 a bottle, comes as the Petaluma, Calif.-based company, short on cash, is gearing up to raise money through a stock sale to investors, according to a source familiar with the plans.

Microcyn is a liquid- and gel-based antiseptic sold over the counter for $20 a bottle. The FDA allows Oculus to market Microcyn as a wound cleaner under the agency's regulation of simple medical devices known as 510(k) approvals. ...